Staril

Quick links to important sections

Staril

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Staril

Quick Facts

Property Description
Active ingredient Fosinopril sodium
Form Oral tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) inhibitor
Common use Cardiovascular support
Origin Synthetic, Pro-drug

What is Staril and What Does it Contain?

Staril is a prescription-only medication dispensed as an oral tablet containing the active substance Fosinopril sodium. This medicine is a synthetic, single-ingredient product utilized in cardiovascular management. Fosinopril is notable as a pro-drug; it is biologically inactive upon administration and is subsequently converted in the body to its active therapeutic form, Fosinoprilat. The final tablet preparation includes the active ingredient alongside standard solid oral excipients required for stability and proper absorption.

Staril’s Pharmacological Classification and Origin

Staril belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class of drugs, positioning it as a core cardiovascular medicine. The primary function of this drug class is to modulate the body’s Renin-Angiotensin-Aldosterone System (RAAS). Fosinopril is an ACE inhibitor with antihypertensive properties. Chemically, Fosinopril is distinguished as a non-sulfhydryl ACE inhibitor. It is also recognized for its dual-route elimination, a characteristic where the active metabolite is cleared from the body by both the kidneys and the liver.

What is the General Purpose of ACE Inhibitors like Staril?

The general purpose of Staril is centered on promoting vasodilation and easing the workload on the heart. By inhibiting the ACE enzyme, the medication helps to prevent the formation of potent vasoconstrictors, allowing the arteries and veins to relax and widen. This action reduces the resistance in the blood flow pathway, known as systemic vascular resistance (SVR). The overall benefit of this physiological action is to support the cardiovascular system by helping to maintain blood flow under a lower and more stable pressure.

Regulatory References

  1. FDA Label: Fosinopril Sodium

What side effects are possible with Staril?

Possible Side Effects and Safety Information

This information reflects the documented adverse reactions and safety restrictions for Staril as defined in official government regulatory documents.

Serious and Clinically Significant Adverse Reactions

Official regulatory labeling highlights the potential for Angioedema, a rapid and severe swelling of the face, lips, tongue, or throat, which is considered a rare but potentially life-threatening allergic reaction. Severe lowering of blood pressure (Hypotension) may occur, especially at the start of therapy. Other serious reactions noted include liver problems (Hepatic Failure), a severe drop in white blood cell count (Agranulocytosis), and serious allergic responses.

Common Adverse Reactions

Adverse reactions classified as common (Very Common or Common in regulatory reports) include:

  • Dry, persistent cough
  • Dizziness or lightheadedness, particularly when rising from a sitting or lying position
  • Fatigue or weakness
  • Nausea
  • Headache
  • An increase in potassium levels in the blood (Hyperkalemia), which requires specific medical monitoring.

Safety Restrictions and Limitations

Staril is subject to several safety limitations and contraindications:

  • Pregnancy: The medicine is contraindicated (absolutely restricted) for use during the second and third trimesters of pregnancy due to the documented risk of severe harm or death to the developing fetus.
  • Drug Interactions: Use is contraindicated with certain other medications, including aliskiren in patients with diabetes or kidney impairment, and concurrently with sacubitril-containing products (Angiotensin Receptor Neprilysin Inhibitors).
  • Specific Patient Groups: Caution and close monitoring are required when used in patients with pre-existing conditions affecting the kidneys (e.g., bilateral renal artery stenosis) or the liver, or in those with severe heart failure.

Overdose and Emergency Response

Overdose and When to Seek Help

The most common manifestation of an overdose of Staril (Fosinopril sodium) officially documented in regulatory sources is hypotension (abnormally low blood pressure). This can present with associated signs such as dizziness, lightheadedness, and fainting. Excessive or severe hypotension is listed as a potential precursor to serious outcomes, which may include oliguria, progressive azotemia, and, rarely, acute renal failure or death.

Official regulatory guidance mandates that immediate emergency medical attention must be sought for any suspected overdose. Emergency services must be contacted instantly if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management is defined as symptomatic and supportive. For treating hypotension, official instructions include placing the patient in a supine position and, if necessary, administering an intravenous infusion of physiological saline solution for volume expansion. The active metabolite, Fosinoprilat, is noted to be poorly removed by hemodialysis or peritoneal dialysis. Patients with pre-existing heart failure or volume depletion are specifically noted as being at greater risk for symptomatic hypotension following an overdose.

Therapeutic Uses of Staril

Staril (Fosinopril) is commonly used to address conditions related to the chronic stress placed upon the cardiovascular system. It is primarily prescribed for the long-term management of essential hypertension and as a supportive therapy for symptomatic chronic heart failure.

In clinical scenarios, the medication is applied across therapeutic domains involving chronic vascular stress and cardiac functional strain. It helps address symptom clusters that may become intense or disruptive, such as persistent fatigue, reduced exercise capacity, and fluid congestion symptoms like edema.

“Staril is often used when supportive symptom management is appropriate, assisting patients with maintaining functional stability during chronic conditions.”

The medication works to support heart health by lowering high blood pressure and easing the heart’s workload. By assisting with blood pressure control, it may help with managing the long-term risks associated with severe cardiovascular and organ-related issues. Furthermore, it is considered relevant for its supportive role in protecting organ function, particularly the kidneys in high-risk groups such as patients with co-existing diabetes mellitus. This supportive benefit contributes to easing the overall symptom load and helps improve day-to-day comfort.

Quick Fact: Symptom Support
Symptom Domain Cardiac Overload and Fluid Retention
Therapeutic Role Supports the easing of symptoms associated with congestion (e.g., breathlessness, swelling).

Regulatory References

  1. NIH MedlinePlus overview on Fosinopril

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Staril — Official Regulatory Information

This section outlines the official eligibility and non-eligibility requirements for Staril, as defined by authoritative government regulatory documents.


Category Regulatory Status
Populations for whom use is allowed Generally allowed for Adults (18-65 years) who do not have any specific contraindications or limitations documented in the labeling.
Populations for whom use is contraindicated Patients with a known hypersensitivity to the drug or any of its components, and individuals with a history of angioedema or anaphylaxis related to Staril.
Age-related eligibility rules Contraindicated in pediatric patients (children) due to lack of established safety and efficacy. Use in geriatric patients (older adults) requires caution.
Condition-specific eligibility rules Contraindicated in individuals with a history of baseline or recurrent severe hypoglycemia. Restricted use is required for patients with severe renal or hepatic impairment.
Pregnancy and lactation eligibility status Prohibited/Contraindicated for use during Pregnancy and when Breastfeeding.

Official Eligibility Statements:

Regulatory documents define who can and cannot use Staril by establishing absolute prohibitions under Contraindications. The medicine is strictly prohibited for patients with hypersensitivity or a history of specific severe reactions. Eligibility is further restricted across Age-Related groups, with use not established or contraindicated in children. Finally, patients with severe organ impairment or those who are pregnant or breastfeeding are classified as non-eligible or subject to significant conditional limitations as stated in the label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Staril (Fosinopril sodium) has documented interaction patterns that are classified by regulatory authorities based on their mechanistic outcome and clinical significance.

Contraindicated and Restricted Combinations

Co-administration with Sacubitril/valsartan is strictly contraindicated; a 36-hour separation period is required when switching between these agents due to the risk of angioedema. Use with Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment. Procedural constraints prohibit the use of Staril in patients undergoing apheresis procedures involving High-Flux Membranes or Dextran Sulfate absorption due to the risk of anaphylactoid reactions.


Pharmacodynamic and Exposure Interactions

Staril co-administered with Potassium-Sparing Diuretics or Potassium Supplements carries an increased risk of hyperkalemia (additive pharmacodynamic effect). Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and is associated with an increased risk of renal function deterioration, particularly in elderly or volume-depleted patients. Staril reduces the renal clearance of Lithium, which can lead to increased serum levels and toxicity. Conversely, Antacids reduce the overall absorption of the active metabolite, Fosinoprilat, requiring a mandatory 2-hour separation between the doses of Staril and antacids.

Mechanism of Action

How Staril Works: Mechanism of Action

Staril modifies pathways associated with dysregulated physiological signaling. Its mechanism of action involves precise interaction with key molecular targets, resulting in the adjustment of biological pathways.


Modulation of Receptor-Mediated Signaling

Staril operates as a selective modulator by binding to specific receptor subtypes within the affected biological system. This engagement either initiates or suppresses downstream signaling sequences, which normally lead to a heightened physiological response. The result is the modification of early molecular steps, modifying mediator activity levels and altering pathway activity.


Influencing Autonomic Pathway Activity

The compound engages mechanisms that regulate overactive processes predominantly within systems where specific transmitters or mediators dominate. Staril modifies the activity of pathways associated with heightened physiological responses, such as those governing autonomic nervous system function. By altering this pathway activity, Staril influences the dynamics of overactive physiological responses, leading to changes in system-level signaling patterns.

Dosage and Administration Information

Staril is administered exclusively via the oral route as a standard tablet containing Fosinopril sodium. The drug is intended for long-term management of chronic cardiovascular conditions and requires a defined, gradual introduction protocol.

The primary dosing regimen involves taking the tablet once daily. For managing hypertension, therapy typically starts with 10 mg once daily, and the dosage is gradually increased (titrated) over several weeks based on clinical response to a maintenance range, which commonly spans 20 mg to 40 mg daily, with a maximum dose of 80 mg. In the case of chronic heart failure, the initial dose is also 10 mg, and while the maintenance range is similar, the official maximum daily dose is limited to 40 mg. The tablet may be taken with or without food as the extent of absorption is not significantly affected.

Specific populations require modification to the initial approach. For patients with moderate to severe renal impairment or those on vigorous diuresis, the official starting dose is reduced to 5 mg once daily to manage physiological responsiveness. Furthermore, the official instructions for a missed dose advise taking it as soon as possible, but strictly mandate skipping the missed dose if it is close to the time for the next scheduled dose, thereby preventing double dosing.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Staril

Evidence for Use in Managing Essential High Blood Pressure (Hypertension)

The clinical evaluation of Staril (Fosinopril) for high blood pressure was primarily conducted through Randomized Controlled Trials (RCTs). Research examined outcomes related to systemic or functional imbalance, such as changes in seated and standing systolic and diastolic blood pressure (BP) over short and intermediate time intervals. Studies also monitored the achievement of pre-defined BP goals.

In the studies, findings indicate that administration of Staril reported measurements related to a decrease in BP in patients with mild to moderate essential hypertension. Research describes patterns related to BP measurements observed early in the study period, and studies reported that the maximum measured reduction in BP may require several weeks of therapy. Certain trials also explored the drug's effect when used alongside other classes of medications, such as thiazide diuretics.

Evidence for Use in Supporting Chronic Heart Failure (CHF)

Staril was evaluated in patients with symptomatic Chronic Heart Failure (CHF), specifically those with mild to moderately severe functional limitations. Core research consisted of double-blind, placebo-controlled RCTs, often applied in studies examining patient-reported experiences while patients were also receiving background therapies like diuretics. Primary research examined outcomes reflecting daily functioning or activity level, such as maximal exercise time, and patient-reported outcomes describing discomfort, including symptoms of fatigue and dyspnea.

Studies monitored the occurrence of prospectively defined clinical events indicative of heart failure worsening, such as hospitalizations. Studies monitored the occurrence of clinical deterioration events, with the reported frequency being tracked between the groups during the follow-up.

Evidence for Use in Organ Protection (Diabetic Nephropathy)

Research also examined the use of Staril in conditions involving physiological strain on the kidneys, particularly in hypertensive patients with Type 2 Diabetes Mellitus who showed signs of early kidney involvement (microalbuminuria). This research involved RCTs and long-term studies, which focused on outcomes related to systemic imbalance, specifically changes in urinary albumin excretion (a key biomarker) and the maintenance of filtration markers.

Findings indicate that treatment with Staril reported measurements related to a change in urinary albumin excretion in these microalbuminuric populations. Research describes patterns related to the maintenance of kidney function markers over follow-up periods ranging up to a few years.

Summary of Research Gaps and Uncertainties

The evidence base has defined limitations. Certainty remains low for definitive outcomes related to long-term survival specifically derived from individual Staril trials, rather than class-level data. The follow-up durations were limited in many of the core trials that evaluated functional outcomes. Subgroup findings are uncertain in some specialized areas, such as the dose-response relationship in children. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Fosinopril: MedlinePlus Drug Information
  2. Fosinopril Efficacy/Safety Trial (FEST): a study of the safety and efficacy of fosinopril in severe heart failure
  3. Guideline for the pharmacological treatment of hypertension in adults

Frequently Asked Questions (FAQ)

Common questions about Staril (FAQ)

Q: How quickly does Staril typically start working?

According to regulatory documents, the initial blood pressure-lowering effect of Staril can be seen within one hour of taking a single dose. The maximum reduction in blood pressure from that single dose is often observed within 3 to 6 hours. For the maximum overall therapeutic benefit of the medicine, continuous therapy over several weeks is usually required.


Q: Are there common side effects of Staril that usually go away?

Official consumer information lists common adverse reactions such as cough, dizziness, and nausea that patients may experience. The documents note that the severity and resolution of side effects can vary by individual. Official information suggests consulting a healthcare provider if any side effects are persistent or become bothersome.


Q: Is it common to feel dizzy when starting Staril?

Dizziness or feeling light-headed is listed as a common reaction in official safety data. This is noted to be most likely to occur at the start of therapy, or after a change in dosage, due to the initial effect of the medication on blood pressure.


Q: Does Staril interact with over-the-counter pain relievers like Ibuprofen?

Regulatory warnings indicate an interaction risk between Staril (an ACE inhibitor) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes Ibuprofen. This combination may diminish the blood pressure-lowering effect of Staril and is associated with an increased potential for kidney function changes, especially in certain individuals.


Q: What is the longest period someone can usually take Staril?

Regulatory documents state that Staril is indicated for the long-term management of chronic cardiovascular conditions like high blood pressure and heart failure. The official labeling does not specify a maximum duration or time limit for how long continuous therapy can be used.


Q: Does Staril require any special monitoring or blood tests?

Official documents indicate that monitoring may involve periodic blood tests to check levels like potassium (hyperkalemia) and to assess kidney and liver function. This monitoring is to check for potential changes associated with the medication.


Q: How does Staril compare generally to other medicines for the same condition?

Staril is classified as one medicine in the Angiotensin-Converting Enzyme (ACE) inhibitor class of drugs. This class is described by regulatory bodies as working to modify the body’s system for blood vessel control to support cardiovascular function. Official information does not make any claims comparing its effectiveness to other medicines in the same or other classes.


Q: Can Staril affect driving ability or concentration?

Official information lists common side effects that include dizziness, light-headedness, and fatigue. Official guidance suggests that due to these side effects, individuals should use caution when driving or operating machinery until they understand how the medicine affects them.


Q: How long does Staril stay in your system after the last dose?

The effective half-life for the active form of the drug, Fosinoprilat, is approximately 11.5 hours in patients with normal kidney function. This half-life may be slightly longer in individuals with heart failure, averaging about 14 hours.


Q: Why is Staril sometimes taken with another specific drug?

Official research and guidelines show that Staril is often used as part of a combination therapy. For chronic heart failure, it is typically used with diuretics and sometimes digitalis. For high blood pressure, it has been studied and used in combination with thiazide diuretics to help achieve optimal control.


Q: Will Staril cure my condition or just manage symptoms?

Official sources confirm that Staril does not cure chronic conditions such as high blood pressure or heart failure. It is officially indicated for the control and long-term management of these conditions.


Q: Is Staril used for conditions other than the primary one listed?

Regulatory documents list the approved uses: high blood pressure and heart failure. Research evidence also supports its use for addressing signs of early kidney involvement (microalbuminuria) in certain hypertensive patients with Type 2 Diabetes Mellitus. Any other uses would be at the direction of a healthcare professional.


Q: Does Staril affect sleep or cause insomnia?

Official documentation lists insomnia (difficulty sleeping) and mood changes as potential adverse reactions that have been associated with the use of Staril.


Q: Can Staril be taken with high blood pressure medication?

Staril is often used in combination with other classes of blood pressure medications, such as diuretics. However, it is strictly contraindicated (prohibited) for use with specific drugs like Sacubitril/valsartan and Aliskiren in certain patient groups, as defined in regulatory labeling.


Q: Are there any specific foods or drinks to avoid while taking Staril?

The official labeling does not list general foods or drinks to avoid. However, there is a specific warning about the increased risk of high potassium levels (hyperkalemia) when Staril is taken with substances that contain high amounts of potassium, such as potassium supplements or salt substitutes. Official warnings suggest that this may require specific monitoring.


Q: Does alcohol change the way Staril works?

Official interaction information notes that Staril and alcohol (ethanol) may have additive effects in lowering blood pressure. This combination may increase the risk of symptoms like dizziness, light-headedness, or fainting.


Q: Can Staril make me feel tired or lethargic?

Official safety information lists fatigue, tiredness, weakness, and drowsiness as potential adverse reactions reported in clinical trials.


Q: Is a metallic taste in the mouth listed as a side effect of Staril?

Official safety data for the ACE inhibitor class notes that a decreased ability to taste or a metallic taste is a potential, though less common, side effect.


Q: What percentage of people experience the most common side effects of Staril?

Official clinical trial data typically lists specific incidence rates (percentages) for common side effects compared to placebo. For example, in heart failure trials, the incidence of dizziness was reported as 11.9% and cough as 9.7% of patients.


Q: When was Staril first approved for use?

The active ingredient in Staril, Fosinopril, was first approved by the U.S. Food and Drug Administration (FDA) in May 1991.


Q: Is the medication Staril addictive?

Staril is a prescription cardiovascular medicine. Regulatory documents and official scheduling records do not list Fosinopril as a controlled substance, and official labeling does not describe it as having addiction or abuse potential.


Q: Are there known interactions between Staril and herbal supplements?

The official labeling does not provide a comprehensive list of all herbal supplements. However, it specifically warns against using substances that increase potassium levels, which may include certain herbal products, due to the risk of high potassium levels (hyperkalemia).


Q: Are there common interactions between Staril and vitamin supplements?

Official warnings regarding the risk of high potassium levels (hyperkalemia) specifically note that some multivitamins contain potassium in small amounts. Official warnings suggest that this may require specific monitoring.


Q: Why is Staril sometimes prescribed to older adults?

Research has examined the use of Staril in older adults. A key feature is its dual-route elimination (cleared by both the kidney and the liver), which means a dose adjustment may be less frequently required despite the common age-related reduction in kidney function.


Q: Does Staril cause dry mouth or increased thirst?

Official consumer information lists dry mouth and thirst as potential symptoms. Official guidance suggests these should be reported to a healthcare provider, particularly if they are severe or associated with other symptoms like excessive vomiting or diarrhea.


Q: What are the general expectations for a person starting Staril?

General expectations are that the medication is for long-term management of a chronic condition, not a cure. The initial blood pressure-lowering effect may be noticed within hours, but the maximum benefit usually takes several weeks of continuous therapy to achieve.


Q: Do people typically switch from another drug to Staril?

Regulatory documents address the practice of switching between certain drugs. For instance, a strict 36-hour wash-out period is required when a patient switches from a Sacubitril-containing product to Staril. This indicates that switching between certain drug classes is a regulated clinical practice.


Q: Is Staril linked to changes in mood?

Official safety data lists mood changes and nervousness as side effects that have been reported in clinical trials.


Q: Is it possible to take too much Staril?

Official consumer information sheets include a protocol for patients to contact a poison control center or emergency services in the event of a suspected overdosage.


Q: Can Staril cause digestive issues like diarrhea or constipation?

Official documents list nausea, vomiting, diarrhea, and abdominal pain as common side effects reported in clinical trials. Constipation is generally not listed as a common adverse reaction.

How should Staril be stored and disposed of?

How to Store and Dispose of Staril?

The storage and disposal instructions for Staril (Fosinopril sodium) are governed by official regulatory standards to maintain the tablet's integrity and ensure safety.

Storage Requirement Specification
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and protected from light and moisture.
Packaging Store only in the original container.

Staril must be kept out of the reach and sight of children at all times. For disposal, any unused or expired tablets must be discarded according to local regulations. Official guidance recommends using a drug take-back program. If a take-back program is unavailable, disposal may be done in household trash after mixing the tablets with an unpalatable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Staril found in:

A-Z Index: